Participants 123 331 7
patients with common cancers involving bone receiving intravenous bisphosphonate therapy for either pamidronate (P) or zoledronic acid (Z) and their preference for the location of the infusion (clinic or home
Participants 476 622 7
Enrolled in the study were 184 patients, and all received initial infusions of Z (so any first infusion reactions did not confound preferences for
Participants 1758 1843 4
Cancer patients prefer shorter bisphosphonate infusions-and at home, where practical.
